Skip to main content

 Scientific publications

PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.

Authors : Amato O, Buisseret L, Gebhart G, Plouznikoff N, Larsimont D, Awada A, Piccart M, Aftimos P
Year : 2023
Journal : Cold Spring Harb Mol Case Stud

[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.

Authors : Iqbal R, Yaqub M, Bektas HO, Oprea-Lager DE, de Vries EGE, Glaudemans AWJM, Aftimos P, Gebhart G, Beelen AP, Schuit RC, Windhorst AD, Boellaard R, Menke-van der Houven van Oordt CW
Year : 2023
Journal : Clin Cancer Res

Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.

Authors : Pérez-García JM, Gebhart G, Borrego MR, Schmid P, Marmé F, Prat A, Dalenc F, Kerrou K, Colleoni M, Braga S, Malfettone A, Sampayo-Cordero M, Cortés J, Llombart-Cussac A
Year : 2022
Journal : Future Oncol
Volume : 18
Pages : 3677-3688

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.

Authors : Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, Macpherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM
Year : 2022
Journal : Eur J Cancer
Volume : 164
Pages : 39-51

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Authors : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Year : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 125

Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

Authors : Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A
Year : 2021
Journal : Lancet Oncol
Volume : 22
Pages : 858-871

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.

Authors : Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart M, Sotiriou C, Jamieson SMF
Year : 2020
Journal : Br J Cancer
Volume : 122
Pages : 603-612

Added value of para-aortic surgical staging compared to <sup>18</sup>F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: An ONCO-GF study.

Authors : De Cuypere M, Lovinfosse P, Goffin F, Gennigens C, Rovira R, Duch J, Fastrez M, Gebhart G, Squifflet JL, Luyckx M, Charaf G, Crener K, Buxant F, Bucella D, Jouret M, Hustinx R, Kridelka F
Year : 2020
Journal : Eur J Surg Oncol
Volume : 46
Pages : 883-887

How COVID-19 pandemic affected cancer progression: Three different scenarios evidenced by PET imaging.

Authors : Mileva M, Artigas C, Gebhart G, Flamen P, Karfis I
Year : 2020
Journal : Hell J Nucl Med
Volume : 23
Pages : 349-353

Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.

Authors : Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van t Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G
Year : 2019
Journal : Clin Pharmacol Ther
Volume : 106
Pages : 148-163

Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.

Authors : deSouza NM, Liu Y, Chiti A, Oprea-Lager D, Gebhart G, Van Beers BE, Herrmann K, Lecouvet FE
Year : 2018
Journal : Eur J Cancer
Volume : 91
Pages : 153-163

N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging.

Authors : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaeys G, Goldman S, Flamen P, Ghanem G
Year : 2017
Journal : Oncotarget
Volume : 8(34)
Pages : 56185-56198

HER2-positive breast cancer is lost in translation: time for patient-centered research.

Authors : Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M
Year : 2017
Journal : Nat Rev Clin Oncol
Volume : 14(11)
Pages : 669-681

Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2.

Authors : Gebhart G, Flamen P, de Vries EG, Jhaveri K, Wimana Z
Year : 2016
Journal : J Nucl Med
Volume : 57 Suppl 1
Pages : 81S-8S

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial.

Authors : Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P
Year : 2016
Journal : Ann Oncol
Volume : 27(4)
Pages : 619-24

Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Authors : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaeys G, Goldman S, Ghanem G, Flamen P
Year : 2015
Journal : Mol Imaging Biol
Volume : 17(5)
Pages : 697-703

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO.

Authors : Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart-Gebhart M, Flamen P, Di Cosimo S
Year : 2013
Journal : J. Nucl. Med.
Volume : 54(11)
Pages : 1862-8

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial.

Authors : Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M
Year : 2013
Journal : Breast
Volume : 22(6)
Pages : 1060-5

New PET imaging agents in the management of solid cancers.

Authors : Garcia C, Gebhart G, Flamen P
Year : 2012
Journal : Curr Opin Oncol
Volume : 24(6)
Pages : 748-55